Literature DB >> 15892826

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways.

Joanne Edwards1, John M S Bartlett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15892826     DOI： 10.1111/j.1464-410X.2005.05527.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  38 in total

1.  Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.

Authors:  Lin Yang; Preethi Ravindranathan; Meera Ramanan; Payal Kapur; Stephen R Hammes; Jer-Tsong Hsieh; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2012-03-08

2.  Nuclear receptors CAR and PXR in the regulation of hepatic metabolism.

Authors:  E S Tien; M Negishi
Journal:  Xenobiotica       Date:  2006 Oct-Nov       Impact factor: 1.908

3.  Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.

Authors:  Punit Saraon; Natasha Musrap; Daniela Cretu; George S Karagiannis; Ihor Batruch; Chris Smith; Andrei P Drabovich; Dominique Trudel; Theodorus van der Kwast; Colm Morrissey; Keith A Jarvi; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

4.  Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells.

Authors:  Silke Kaulfuss; Michal Grzmil; Bernhard Hemmerlein; Paul Thelen; Stefan Schweyer; Jürgen Neesen; Lukas Bubendorf; Andrew G Glass; Hubertus Jarry; Bernd Auber; Peter Burfeind
Journal:  Mol Endocrinol       Date:  2008-05-01

5.  Down-regulation of androgen-receptor and PSA by phytochemicals.

Authors:  Sophie Chen; Jian Gao; H Dorota Halicka; Frank Traganos; Zbigniew Darzynkiewicz
Journal:  Int J Oncol       Date:  2008-02       Impact factor: 5.650

6.  Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells.

Authors:  Katayoon H Emami; Lisha G Brown; Tiffany E M Pitts; Xizhang Sun; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

7.  Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

Authors:  Punit Saraon; Daniela Cretu; Natasha Musrap; George S Karagiannis; Ihor Batruch; Andrei P Drabovich; Theodorus van der Kwast; Atsushi Mizokami; Colm Morrissey; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2013-02-26       Impact factor: 5.911

Review 8.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

9.  [Value of targeted therapy for prostate cancer].

Authors:  C Börgermann; F Vom Dorp; M Schenck; M Becker; J Hess; H Rübben
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

Review 10.  [Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches].

Authors:  L Rinnab; A Hessenauer; S V Schütz; E Schmid; R Küfer; F Finter; R E Hautmann; K D Spindler; M V Cronauer
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.